Loading patent…
AssigneeZora Biosciences Oy
InventorsReijo Laaksonen, Kim Ekroos, Reini Hurme, Minna Jänis, Riikka Katainen, Kirill Tarasov
Estimating the term…
The present invention inter alia provides a method, and uses thereof, of predicting statin-induced muscle toxicity or its complications, such as myalgia, myopathy and rhabdomyolysis, by detecting the lipid concentrations or lipid-lipid concentration ratios of a biological sample and comparing them to a control. This method has identified lipid markers that are more specific and sensitive in detecting these statin-induced muscle toxicity than the currently utilized clinical markers. Also provided is an antibody towards said lipids, and the use thereof for predicting, diagnosing, statin-induced muscle toxicity. The invention additionally relates to kits comprising lipids and/or an antibody thereto, for use in the prediction and/or diagnosis of statin-induced muscle toxicity.
A method for determining whether a subject is at risk to develop, or is suffering from statin-induced muscle toxicity and/or one or more of its complications, comprising
A method for determining whether a subject is at risk to develop, or is suffering from statin-induced muscle toxicity and/or one or more of its complications, wherein the subject is female, comprising determining in a sample from said subject the concentration(s) of one or more lipid(s), wherein (a) decreased concentration(s) in said sample, when compared to a control, is (are) indicative of said subject suffering from said statin-induced muscle toxicity and/or said complication(s), wherein the one or more lipid(s) whose decrease in concentration is (are) compared to the control is (are) selected from:
A method for determining whether the treatment with a statin and/or a lipid lowering drug of a subject needs adjustment, comprising
A method for determining whether the treatment with a statin and/or a lipid lowering drug of a subject needs adjustment, wherein the subject is female, comprising determining in a sample from said subject the concentration(s) of one or more lipid(s), wherein (a) decreased concentration(s) in said sample, when compared to a control, is (are) indicative of said treatment requiring adjustment, wherein the one or more lipid(s) whose decrease in concentration is (are) compared to the control is (are) selected from:
Dependencies are inferred from the claim text.